title: The next step toward GMP-grade production of engineered immune cells.
abstract: Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunotherapy.
authors.affiliation: Laboratory of Translational Immunology, University Medical Center Utrecht , Utrecht, The Netherlands.
authors.forename: Guido J J
authors.initials: GJ
authors.lastname: Kierkels
authors.affiliation: Laboratory of Translational Immunology, University Medical Center Utrecht , Utrecht, The Netherlands.
authors.forename: Trudy
authors.initials: T
authors.lastname: Straetemans
authors.affiliation: Department of Hematology, University Medical Center Utrecht , Utrecht, The Netherlands.
authors.forename: Moniek A
authors.initials: MA
authors.lastname: de Witte
authors.affiliation: Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Kuball
keywords: Adoptive immunotherapy; GMP-grade production; T cell subsets; allogeneic stem cell transplantation